American Superconductor (AMSC) closed at $7.58 in the latest trading session, marking a -0.52% move from the prior day.

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

American Superconductor (AMSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

American Superconductor (AMSC) delivered earnings and revenue surprises of -6.67% and 16.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Relief Rally Snaps the Dow's 5-Day Losing Skid

AYER, Mass., Feb. 03, 2020 -- AMSC (NASDAQ: AMSC), a global energy solutions provider serving wind and power grid industry leaders, announced today that it plans to release its.

American Superconductor has been struggling lately, but the selling pressure may be coming to an end soon.

Dan McGahn has been the CEO of American Superconductor Corporation (NASDAQ:AMSC) since 2011. This analysis aims first...

The fear of the coronavirus spreading further afield hasn’t dampened investors’ appetite. The major indexes continue to trade at all-time highs, with both the S&P 500 and Nasdaq Composite touching new milestones earlier this week.According to Canaccord's chief market strategist Tony Dwyer there are several reasons the outlook for the markets remains bullish. “You have full employment with easy money and high money availability, high confidence and a millennial demographic that’s going into the household formation years,” he said.With this in mind, we pulled up three of Canaccord’s recent stock picks which the renowned investment firm thinks can soar in the coming months – by over 50% each, as it happens. Just to be safe, we run them through TipRanks Stock Screener tool to ensure that other analysts agree with Canaccord. Let’s take a closer look.SeaSpine Holdings (SPNE)SeaSpine’s 2020 has gotten off to a bright start; the medical device company is up by 36% year-to-date. According to Cannacord’s Kyle Rose, there is yet more to come.SeaSpine designs, develops and sells surgical equipment for the treatment of spinal disorders. The company's ever-expanding portfolio of products has been growing impressively; 22 launches between 2016-2018, 7 more last year and a further 12 expected this year.The global spinal implant market is the largest division within the musculoskeletal space and is worth over $10 billion. The space is ideally suited to smaller, pure play companies such as SeaSpine, as the spine market’s focus on education and physician relationships rewards innovation. The company has strategically invested in its sales arm and has a strong distribution channel, too.Rose sees “smooth sailing and share-taking ahead for SPNE in 2020." The 5-star analyst cites new products, improving distribution and a clean balance sheet as reasons to be optimistic.He said, “SeaSpine management has clearly put an emphasis on new product development in order to differentiate away from an older, legacy portfolio. New, innovative products are not only key to fighting off competitive pressures, but also crucial for retaining the mindshare of distributors as the company works to retain key existing distributors and transition to exclusive relationships that incentivize near and long-term growth.”It's no surprise to learn, then, that Rose initiated coverage of SPNE with a Buy rating. The price target of $25 conveys the analyst’s belief SeaSpine can add an extra 55% to its share price over the next 12 months. (To watch Rose’s track record, click here)The Street adjusts its posture and concurs; SeaSpine’s Moderate Buy consensus rating breaks down into 5 Buys and 1 Sell. At $20.50, the average price target indicates further possible upside of 27%. (See SeaSpine stock analysis on TipRanks)American Superconductor (AMSC)From spinal solutions to solving energy issues, where we come across American Superconductor. The energy technology company designs and manufactures power systems and superconducting wire, providing megawatt-scale solutions across the globe. The company has a two -pronged approach, focusing both on Wind and Grid.According to Canaccord’s Chip Moore, AMSC’s management of power flows are tied to several attractive long-term secular drivers. The 5-star analyst notes that with distributed generation assets on the rise and accelerating adoption of electric vehicles, the need for increased grid reliability is key. AMSC’s REG (Resilient Electric Grid) links together critical substations via its Amperium HTS wire (which allows systems to flexibly redirect power) which, in turn, helps tackle this issue in urban environments. The first key project (ComEd) is making headway in Chicago, with more to come should it prove a success.Moore noted, “We find management making good strides in commercialization of several attractive markets (beyond wind), supporting reduced future volatility and what we view as a path toward sustainable cash generation. With ~$68M of cash and investments on the balance sheet, a more reasonable valuation following last year’s pullback, and a rapidly approaching breakeven (~$25M of sales per quarter), we see good future potential for aggressive growth-type investors.”What does it mean, then? It means the 5-star analyst initiates coverage of AMSC with a Buy rating. Moore sets a price target of $13, indicating potential upside of 65%. (To watch Moore’s track record, click here)The grid is currently operating quietly on the Street, with only one additional analyst chiming in with a view on AMSC’s prospects. The additional Buy, though, means the energy solutions provider rates as a Moderate Buy. With an average price target of $13.5, investors could be pocketing a 72% gain over the coming months. (See American Superconductor stock analysis on TipRanks)Akero Therapeutics (AKRO)This clinical-stage biotech was only founded in 2017 and went public in June of last year. Akero Therapeutics might be a young company but has already been turning heads on the Street; Its share price is up by 54% since its first day on the market.The company’s focus is on the development of medicines to reverse the course of serious metabolic diseases, specifically ones with high unmet medical needs (orphan diseases).Akero’s lead candidate is AKR-001, a treatment for NASH disease (Non-Alcoholic SteatoHepatitis), a fatty liver disease, for which there are currently no specific drugs available. The market for NASH medications is expected to increase considerably over the next few years, and whoever will bring a viable solution to into play stands to cash in handsomely. The drug is currently in a Phase 2 trial with top-line data expected this quarter.Following promising data from a Phase 1 trial, Cannacord’s Edward Nash believes Akero’s AKR-01 “has demonstrated superior molecule design advantages.” Furthermore, the 4-star analyst thinks Akero has an impressive management team with “significant biotech and pharma financing, drug development, regulatory and launch experience.”Nash said, “Our model assumes a NASH population with stage 1-3 fibrosis, a 35% diagnosis rate and 80% treatment rate, resulting in a 2.1M target market eligible for AKR-001 treatment. Assuming a modest 5% penetration rate in 2029, the out-year of our model, and pricing in-line with branded type 2 diabetes medications, we conservatively project Akero to book worldwide revenue of ~$1.1B. With ~$148M in cash and equivalents reported at the end of 3Q19 we believe the company is well capitalized to achieve meaningful clinical milestones before funding is required.”Accordingly, Nash initiated coverage on the NASH fighter with a Buy rating and a $36 price target. The potential upside, should the target be met, comes in at 52%. (To watch Nash’s track record, click here)What does the Street think of Akero’s prospects? The sole Buy ratings – 5, in fact – bestow a Strong Buy consensus rating on the promising biotech. With an average price target of $32.8, analysts see the potential for a 31% increase to the share price over the coming year. (See Akero stock analysis on TipRanks)

Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

AYER, Mass., Dec. 19, 2019 -- AMSC (NASDAQ: AMSC), a global energy solutions provider serving power grid and wind industry leaders, today announced $11 million of D-VAR®.

In the latest trading session, American Superconductor (AMSC) closed at $8.02, marking a -1.6% move from the previous day.

American Superconductor (AMSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

American Superconductor's (AMSC) fiscal third-quarter results are likely to have benefited from strengthening D-VAR shipments, VVO products and increasing REG revenues.

American Superconductor (AMSC) closed the most recent trading day at $7.56, moving -1.56% from the previous trading session.

AYER, Mass., Feb. 05, 2020 -- AMSC (Nasdaq: AMSC), a global solutions provider serving power grid and wind industry leaders, today reported financial results for its third.

Editor's note: This column is part of InvestorPlace.com's Best Stocks for 2020 contest. Neil George's pick for the contest is Hercules Capital (NYSE:HTGC).Don't ever look at any of your owns stocks and think about what you paid for it. If you are up, great. But it doesn't matter, as each day -- or at least each month -- you need to look at that stock and ask yourself: Would you buy it again, and under what price? And if you are down, the same question applies. Also, it is important to not hold a stock, hoping that it will inch up to your buy price so that you can sell it. The hold-and-hope method never ends well.At the start of this year, I joined my colleagues at InvestorPlace as each of us presented one stock to buy and own for all of 2020. My stock was -- and is -- Hercules Capital (NYSE:HTGC).InvestorPlace - Stock Market News, Stock Advice & Trading TipsLet's get the elephant in the room out of the way first. For the full first quarter of 2020, HTGC stock has dropped by 45.5% in price. After including dividend distributions, the total return is a net loss of 43.9%.Source: Chart courtesy of Bloomberg Hercules Capital (HTGC) Total Return 1Q 2020That's terrible.But as I led in this report, it doesn't matter what the starting price was -- only what it is right now, which is about $7. And that is a pretty nice price to buy HTGC stock. The underlying company has a whole lot of very valuable assets and lots of cash and credit capability. What Is Hercules Capital?Hercules Capital is an alt-financial company providing finance (along with equity participation) to technology companies in various states of development. Technology is one of the better forward-looking segments now. Tech companies are providing solutions for e-commerce, remote management, and also life science products and services. Many of Hercules Capital's highly diversified portfolio companies should continue to advance -- and then some. * 7 Dividend Stocks at Risk of Slashing Payouts Hercules is structured as an investment company, also known as a business development company. The Investment Company Act of 1940 founded these BDCs, and the Small Business Investment Incentives Act of 1980 further codified them.Both of these bits of U.S. law allow Hercules to largely avoid federal income tax. This perk helps it generate more cash, which it uses to fulfill bigger dividend distributions.Hercules is a venture capital-style company that focuses exclusively on tech firms. It provides loans to fund development and helps coach companies through their IPOs. And since its founding in 2003, it has successfully worked with nearly 500 companies. Hercules has brought billions of dollars of value to the markets.Unlike many other BDCs, it does not participate in collateralized loan obligations (CLOs), not is it involved in mortgage loans or mortgage-backed securities (MBS). This limits its risk and provides more transparency to HTGC's shareholders. Hercules Capital's Impressive PortfolioHercules breaks down its numerous portfolio companies into four primary groups. The first is life sciences, which includes drug and therapeutic companies. Then there's general technology, which includes numerous class-leading companies in various businesses. Third is sustainable and renewable energy, and fourth is special opportunity companies.It currently states that its life sciences companies make up half of its current portfolio. The full list of the current portfolio can be found here. And the rest of its portfolio spans many different technologies.Hercules has plenty of bold-faced names that it has worked with over the years. It currently assists FanDuel in the increasingly popular sports gaming market. It has BrightSource Energy in its renewables unit, along with American Superconductor (NASDAQ:AMSC).And Hercules also stands to benefit from the current remote work surge. It has DocuSign (NASDAQ:DOCU) and Evernote, which specializes in cloud document management. It also has innovative food brands including Annie's and Impossible Foods. For those seeking family information, it has 23andMe and Ancestry.com. Hercules truly has something for everyone.It's important to note that the financing isn't just about making loans to these companies. Hercules also gets equity stakes as part of each transaction, which provides it with gains along the way.And Hercules doesn't just sit around waiting for the phone to ring for opportunity. Instead, it is based in the tech mecca of Palo Alto, California. It knows everybody in technology. And it also has strategic offices around the U.S. to help it reach other customers and financial partners.One office I like is its very special team inside the Washington beltway. The U.S. government provides plenty of opportunities for tech companies, and Hercules works to make things happen for its clients.And all of the above comes with $7 HTGC stock. How Is the Lockdown Impacting HTGC Stock?But what is the status of the company while the U.S. economy is in lockdown? For me, status means how the company is going to get through the mess, and how it will perform moving forward. This includes its employees, which are now working remotely. And it also includes it suppliers, which I will get to in a moment. Lastly, it includes its customers, which are the current and future companies it invests in.Here I see that tech is becoming one of the value-focused and dependable parts of the stock market during lockdown. Technology is bringing solutions for everything from healthcare to remote work. And that trend won't stop anytime soon.Now, let's look at the credit status of the company. Its debts are manageable at 52.9% of its assets.And Hercules Capital has a revolving credit line with MUFG Union Bank for working capital that will mature on May 5. It also has a smaller loan maturing in 2022 with another major line of credit. It has placed two mini bonds (bonds that trade like preferred shares) with maturities in 2025 and 2033.Hercules also has cash and cash equivalents amounting to $64 million. The company recently announced that, with various loan payments and pre-payments, it will have $350 million in liquid assets for its first quarter.In addition, it placed additional shares last year for $62.7 million, and some in 2018 for $63.3 million. These two offerings were part of the company's at-the-money capital program of 12 million shares. It has another placement of additional capital which is set to close in June for an additional $70 million.For now, after reviewing its status, I think Hercules Capital and HTGC stock are in pretty good condition. The Bottom Line on HTGC StockHercules distributes dividends both in regular amounts (currently 32 cents per share) and in a special distribution through the year. It paid one of those special distributions of 8 cents on March 9. That brings the annual dividend to a whopping 20.2%. Remember, HTGC stock trades below $7.Under generally accepted accounting principles (GAAP), the cash available for shareholders was $44.6 million and total dividend distributions came in just under $37 million. And its reported retention rate for earnings is at 22.7%. Of course, both of these details are backward-looking, but they give you an idea of its coverage and reinvested capital.And, as Hercules is reporting expectations for heavier cash and liquid assets, the dividend may well remain. Granted, a lot is going on in the economy. But the company survived credit-threatening times before, including the 2007-08 financial crisis, so it has proven its chops.Another thing I like is that its management team, board of directors and other insiders own 4.7% of the company's overall shares. Management has skin in the game with HTGC stock.Source: Chart courtesy of Bloomberg Hercules Capital Book Value Per ShareHTGC stock is now below $7, so it is valued at a discount of 30% of the company's $10.55 book value. This makes it a bit of a bargain right now.I have the shares as a buy ideally in a taxable account under $9.60.Neil George was once an all-star bond trader, but now he works morning and night to steer readers away from traps -- and into safe, top-performing income investments. Neil's new income program is a cash-generating machine … one that can help you collect $208 every day the market's open. Neil does not have any holdings in the securities mentioned above. More From InvestorPlace * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * This Stock Picker's Latest Video Just Went Viral * The 1 Stock All Retirees Must Own The post Best Stocks for 2020: Hercules Capital Stock Is a Steal for $7 appeared first on InvestorPlace.

Q3 2019 American Superconductor Corp Earnings Call

American Superconductor (AMSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

New Strong Buy Stocks for December 24th